A multigene expression score for predicting response to anti-PD-1/PD-L1 therapy for clear cell renal cell cancer patients.

656Background: Anti-PD-1 inhibitor nivolumab and combination checkpoint inhibition (nivolumab and ipilimumab) are approved for advanced clear cell renal cell cancer (ccRCC), with objective response...